Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Treatment of Acute VTE with Rivaroxaban - Results of the Prospective Dresden Noac Registry (NCT01588119)

Loretta Keller, Sandra Marten, MD, Judith Hecker, Sebastian Werth, MD, Luise Tittl, B.Sc., Jan Beyer-Westendorf, MD

Blood (2016) 128 (22): 2618.

https://doi.org/10.1182/blood.V128.22.2618.2618

Published: 2016

Journal Articles

Centrally Adjudicated Cause of Death during Noac Treatment – Results of the Prospective Dresden Noac Registry (NCT01588119)

Franziska Michalski, Sebastian Werth, MD, Christina Köhler, MD, Luise Tittl, Katharina Daschkow, Jan Beyer-Westendorf, MD

Blood (2014) 124 (21): 2876.

https://doi.org/10.1182/blood.V124.21.2876.2876

Published: 2014

Journal Articles

Characteristics of Atrial Fibrillation Patients Not Switched from Vka to Noac and Persistence on Vka – a Subgroup Analysis of the Prospective Dresden Noac Registry (NCT01588119)

Jan Beyer-Westendorf, MD, Franziska Michalski, Sebastian Werth, MD, Luise Tittl, Christina Köhler, MD, Norbert Weiss, Prof.

Blood (2014) 124 (21): 1538.

https://doi.org/10.1182/blood.V124.21.1538.1538

Published: 2014

Journal Articles

Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation – Final Results of the Prospective Noac Registry (NCT01588119)

Franziska Ebertz, Sebastian Werth, MD, Christina Köhler, MD, Franziska Michalski, Ulrike Hänsel, Luise Tittl, Katharina Daschkow, Thomas Schreier, Jan Beyer-Westendorf, MD

Blood (2014) 124 (21): 1541.

https://doi.org/10.1182/blood.V124.21.1541.1541

Published: 2014

Journal Articles

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry

Jan Beyer-Westendorf, Kati Förster, Sven Pannach, Franziska Ebertz, Vera Gelbricht, Christoph Thieme, Franziska Michalski, Christina Köhler, Sebastian Werth, Kurtulus Sahin, Luise Tittl, Ulrike Hänsel, Norbert Weiss

Blood (2014) 124 (6): 955–962.

https://doi.org/10.1182/blood-2014-03-563577

Published: 2014

Includes: Supplemental data

Journal Articles

Acute Treatment Of Pulmonary Embolism With Rivaroxaban - Real Life Data From The Prospective Dresden Noac Registry (NCT01588119)

Christina Köhler, MD, Sebastian Werth, MD, Luise Tittl, Jan Beyer-Westendorf, MD

Blood (2013) 122 (21): 2380.

https://doi.org/10.1182/blood.V122.21.2380.2380

Published: 2013

Journal Articles

Changes Of Coagulation Activation Parameters After Discontinuation Of VTE Treatment With Vitamin-K Antagonists, Apixaban, Rivaroxaban Or Dabigatran and Impact On Clinical Outcome After 12 Months

Sebastian Werth, MD, Christina Köhler, MD, Siegmund Gehrisch, Thoralf Stange, Jan Beyer-Westendorf, MD

Blood (2013) 122 (21): 3647.

https://doi.org/10.1182/blood.V122.21.3647.3647

Published: 2013

Journal Articles

Pattern and Management Of Bleeding Complications With Novel Oral Anticoagulants – Results Of The Prospective Dresden Noac Registry (NCT01588119)

Kati Förster, Franziska Ebertz, Vera Gelbricht, Denise Röllig, Luise Tittl, Christina Köhler, MD, Sebastian Werth, MD, Jan Beyer-Westendorf, MD

Blood (2013) 122 (21): 214.

https://doi.org/10.1182/blood.V122.21.214.214

Published: 2013

Journal Articles

Hospitalization or Outpatient Treatment for Acute Pulmonary Embolism - a Retrospective Cohort Study of 439 Consecutive Patients with Community-Aquired Pulmonary Embolism

Sebastian Werth, MD, Virginia Kamvissi, Eberhard Kuhlisch, Jan Beyer-Westendorf, MD

Blood (2012) 120 (21): 3416.

https://doi.org/10.1182/blood.V120.21.3416.3416

Published: 2012

Journal Articles

Real Life Efficacy and Safety of Rivaroxaban for Extended VTE Treatment – First Results of the Prospective Noac Registry (NCT01588119).

Christina Koehler, Sebastian Werth, MD, Vera Gelbricht, Ulrike Haensel, Luise Tittl, Ines Beyer-Westendorf, Thomas Schreier, Maria Eulitz, Jan Beyer-Westendorf, MD

Blood (2012) 120 (21): 2267.

https://doi.org/10.1182/blood.V120.21.2267.2267

Published: 2012

Journal Articles

Real Life Efficacy and Safety of Rivaroxaban for Stroke Prevention in Atrial Fibrillation – First Results of the Prospective Noac Registry (NCT01588119)

Sebastian Werth, MD, Christina Koehler, Vera Gelbricht, Ulrike Haensel, Luise Tittl, Ines Beyer-Westendorf, Thomas Schreier, Jan Beyer-Westendorf, MD

Blood (2012) 120 (21): 1156.

https://doi.org/10.1182/blood.V120.21.1156.1156

Published: 2012

Journal Articles

Real Life Efficacy and Safety of Rivaroxaban for Acute VTE Treatment – First Results of the Prospective Noac Registry (NCT01588119)

Vera Gelbricht, Christina Koehler, Sebastian Werth, MD, Ulrike Haensel, Thomas Schreier, Maria Eulitz, Luise Tittl, Ines Beyer-Westendorf, Jan Beyer-Westendorf, MD

Blood (2012) 120 (21): 1159.

https://doi.org/10.1182/blood.V120.21.1159.1159

Published: 2012

Journal Articles

Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation – First Results of the Prospective Noac Registry (NCT01588119)

Vera Gelbricht, Sebastian Werth, MD, Christina Koehler, Ulrike Haensel, Luise Tittl, Ines Beyer-Westendorf, Thomas Schreier, Jan Beyer-Westendorf, MD

Blood (2012) 120 (21): 502.

https://doi.org/10.1182/blood.V120.21.502.502

Published: 2012

Journal Articles

Hair Loss Is a Potential Side Effect of Novel Oral Anticoagulants – Findings From the Dresden Noac Registry (NCT01588119)

Vera Gelbricht, Christina Koehler, Sebastian Werth, MD, Ulrike Haensel, Thomas Schreier, Tittl Luise, Maria Eulitz, Ines Beyer-Westendorf, Jan Beyer-Westendorf, MD

Blood (2012) 120 (21): 1173.

https://doi.org/10.1182/blood.V120.21.1173.1173

Published: 2012

Journal Articles

Efficacy and Safety of VTE Prophylaxis with Oral Rivaroxaban Compared to Fondaparinux or Low-Molecular Weight Heparin In a Large Cohort of Consecutive Patients Undergoing Major Orthopaedic Surgery

Jan Beyer-Westendorf, MD, Lars Donath, Jörg Lützner, MD, Sebastian Werth, MD, Oliver Radke, MD, Klaus-Peter Guenther, Prof., Norbert Weiss, Prof.

Blood (2011) 118 (21): 210.

https://doi.org/10.1182/blood.V118.21.210.210

Published: 2011

NARROW

Treatment of Acute VTE with Rivaroxaban - Results of the Prospective Dresden Noac Registry (NCT01588119)

Centrally Adjudicated Cause of Death during Noac Treatment – Results of the Prospective Dresden Noac Registry (NCT01588119)

Characteristics of Atrial Fibrillation Patients Not Switched from Vka to Noac and Persistence on Vka – a Subgroup Analysis of the Prospective Dresden Noac Registry (NCT01588119)

Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation – Final Results of the Prospective Noac Registry (NCT01588119)

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry

Acute Treatment Of Pulmonary Embolism With Rivaroxaban - Real Life Data From The Prospective Dresden Noac Registry (NCT01588119)

Changes Of Coagulation Activation Parameters After Discontinuation Of VTE Treatment With Vitamin-K Antagonists, Apixaban, Rivaroxaban Or Dabigatran and Impact On Clinical Outcome After 12 Months

Pattern and Management Of Bleeding Complications With Novel Oral Anticoagulants – Results Of The Prospective Dresden Noac Registry (NCT01588119)

Hospitalization or Outpatient Treatment for Acute Pulmonary Embolism - a Retrospective Cohort Study of 439 Consecutive Patients with Community-Aquired Pulmonary Embolism

Real Life Efficacy and Safety of Rivaroxaban for Extended VTE Treatment – First Results of the Prospective Noac Registry (NCT01588119).

Real Life Efficacy and Safety of Rivaroxaban for Stroke Prevention in Atrial Fibrillation – First Results of the Prospective Noac Registry (NCT01588119)

Real Life Efficacy and Safety of Rivaroxaban for Acute VTE Treatment – First Results of the Prospective Noac Registry (NCT01588119)

Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation – First Results of the Prospective Noac Registry (NCT01588119)

Hair Loss Is a Potential Side Effect of Novel Oral Anticoagulants – Findings From the Dresden Noac Registry (NCT01588119)

Efficacy and Safety of VTE Prophylaxis with Oral Rivaroxaban Compared to Fondaparinux or Low-Molecular Weight Heparin In a Large Cohort of Consecutive Patients Undergoing Major Orthopaedic Surgery

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only